Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
TEPEZZA: First and Only FDA-Approved Medicine for Patients with Thyroid Eye Disease
Significant Early Interest from Thyroid Eye Disease Community
Received early U.S. FDA approval on Jan. 21, 2020 for patients with thyroid eye disease (TED)
Impressive Phase 3 results show 82.9 percent of TEPEZZA patients with ≥2mm proptosis reduction
•
TED is a debilitating, vision-threatening, rare autoimmune disease that severely impacts
quality of life
•
Inflammation and tissue expansion behind the eye cause proptosis (eye bulging) and diplopia (double vision)
U.S. commercial launch underway following significant pre-launch market education efforts
Multi-functional, highly experienced team has been working with stakeholders since July 2019
More than 500 patient enrollment forms (PEFS) submitted, significantly exceeding our expectations, with
conversion subject to typical reimbursement dynamics and timelines
$
Peak U.S. annual net sales estimate >$1B(1)
HORIZON
(1) Horizon estimate.
Patient enrollment forms, which are similar to benefit investigations, are early indicators of demand.
14View entire presentation